Paris, October 21, 2024 – Eclevar MedTech, a leading european contract research organization (CRO) specializing in medical devices, proudly announces its colleboration with by Asahi intecc (Japan manufacturer of medical device) to provide consulting expertise in clinical evaluation and post-market clinical follow-up (PMCF) strategies in interventional cardiovascular area. This partnership marks a crucial step in the collaboration between the two companies, aiming to enhance innovation and make products of Asahi Intecc compliant to the european requirement of the MDR 745/2017.
ASAHI INTECC is a global leader in the development and manufacturing of medical devices, primarily focused on the cardiovascular field. The company specializes in producing high-quality guidewires, microcatheters, and other interventional products used in minimally invasive procedures to treat complex cardiovascular conditions. Founded in Japan, ASAHI INTECC is renowned for its proprietary technologies in wire drawing, forming, and braiding, which contribute to the superior performance of its devices in navigating challenging vascular anatomy.
With a diverse product portfolio, the company serves various medical specialties, including coronary, peripheral, and neurovascular interventions. ASAHI INTECC aims to enhance patient outcomes by providing cutting-edge medical solutions that enable precise and effective treatments for conditions like coronary artery disease, peripheral arterial disease, and neurovascular disorders
Eclevar MedTech, located in Paris, has quickly established itself since its founding in 2018 thanks to its integrated approach to clinical trials, from pre-commercialization phases to post-market clinical follow-up (PMCF). Eclevar stands out for its ability to provide tech-enabled service tailored medtech industry to overcome clinical challenges related to the MDR 2017/745, leveraging an international team of experts, clinical trial platform that speeds site feasability and qualification, patients identification as well as state of the Art eCOA/ePRO platform. ECLEVAR MEDTECH is backed by healthtech financial capital such as keles and ballas invest. https://keles.care/
Eclevar designs and conducts innovative and efficient clinical studies by leveraging cutting-edge technologies while ensuring flexibility through its MILO Studio platform. This approach ensures seamless global clinical study management, a particularly relevant asset for partners like Asahi Intecc.
Client Feedback:
Seiichi Tanaka, Asahi Intecc: “The evaluation clearly pinpointed compliance issues and areas needing improvement, with color-coded sections making it easy to understand. Eclevar’s thorough explanations during meetings provided valuable insights into the required actions, significantly improving our understanding. The points raised have been instrumental in addressing inquiries from the Notified Body, and we are grateful for your support.”
Chems Hachani, Executive President, Eclevar MedTech: “Working with ASAHI INTECC is a significant opportunity to leverage their renowned expertise in Class III vascular catheter technologies. Their commitment to advancing cardiovascular health aligns perfectly with our mission to deliver exceptional clinical and regulatory solutions. We look forward to contributing to their future success by providing strategic support in clinical evaluation and post-market clinical follow-up, aiming to elevate patient care in vascular interventions.
This partnership represents a pivotal step in driving innovation in the field of advanced cardiovascular therapies, with a focus on optimizing treatment outcomes for complex vascular conditions. By combining our strengths, we aim to set new benchmarks for safety and effectiveness in the use of Class III vascular catheter devices.”
Press Contacts:
ASAHI INTECC
Communications Department
Email: info@asahi-intecc.com
Website: www.asahi-intecc.com
Eclevar MedTech
Public Relations Service
Email: Clientcare@eclevar.com
Website: www.eclevarmedtech.com
About ASAHI INTECC:
ASAHI INTECC is a global leader in the development and manufacturing of advanced medical devices, particularly focused on interventional cardiovascular procedures. With expertise in designing high-performance guidewires, catheters, and microcatheters for coronary, peripheral, and neurovascular applications, ASAHI INTECC aims to improve patient outcomes in complex vascular interventions. Headquartered in Japan, the company’s products are widely used across more than 100 countries, contributing to significant advancements in the treatment of cardiovascular diseases.
About Eclevar MedTech:
Eclevar MedTech is a Paris-based contract research organization (CRO) providing comprehensive services for clinical trials and regulatory compliance in the medical device and in vitro diagnostics sectors. The company specializes in designing and conducting innovative clinical studies using advanced technologies, supported by its flexible MILO Studio platform. Eclevar MedTech’s expertise helps streamline clinical evaluation and post-market surveillance processes, ensuring efficient and compliant product development.
Company identification : Eclevar Medtech UK LTD, 15964075, 124-128 City Road, London, England, EC1V 2NX
